All In Biotech

Drug Trial Radar · NCT04491838

Study of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Manufacturing Processes in Healthy Adult Participants

A Randomized, Open-Label, Parallel Group Study of the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Manufacturing Processes in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Mar 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Aug 3, 2020

Primary completion

Mar 5, 2021

Study completion Mar 5, 2021

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Jul 29, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of the study is to compare the pharmacokinetic(PK) profile of pozelimab produced by the original manufacturing process (Process A) compared to a second manufacturing process (Process B) The secondary objectives of the study are: * Assess the safety and tolerability of a single SC dose of pozelimab produced by the 2 manufacturing processes * Assess the immunogenicity of pozelimab produced by the 2 manufacturing processes

Conditions

  • Healthy Volunteer

Interventions

  • PozelimabDrug

    Single subcutaneous (SC) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess the time of the last positive concentration (AUClast) pharmacokinetic (PK) profile of pozelimab in Process ATime frame: Up to 16 weeks
  2. Assess the time of the last positive concentration (AUClast) PK profile of pozelimab in Process BTime frame: Up to 16 weeks
  3. Assess peak concentration (Cmax) PK profile of pozelimabin in Process ATime frame: Up to 16 weeks
  4. Assess peak concentration (Cmax) PK profile of pozelimab in Process BTime frame: Up to 16 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Regeneron Study Site

    Antwerp, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.